AccueilHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Dernière clôture
25,85 €
Variation sur la journée
25,67 € - 25,67 €
Plage sur l'année
19,52 € - 36,69 €
Capitalisation boursière
3,58 Md USD
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Actualités
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
(USD) | mars 2024info | Variation Y/Y |
---|---|---|
Chiffre d'affaires | — | — |
Charges d'exploitation | 126,19 M | 28,63 % |
Résultat net | -125,30 M | -357,42 % |
Marge bénéficiaire nette | — | — |
Bénéfice par action | -1,02 | -326,67 % |
EBITDA | -121,67 M | -339,34 % |
Taux d'imposition effectif | — | — |
Bilan
Total des actifs
Total du passif
(USD) | mars 2024info | Variation Y/Y |
---|---|---|
Trésorerie/Invest. court terme | 520,91 M | 8,30 % |
Total des actifs | 955,15 M | 7,16 % |
Total du passif | 459,74 M | 7,87 % |
Total des capitaux propres | 495,40 M | — |
Actions en circulation | 124,20 M | — |
Ratio cours/valeur comptable | 6,63 | — |
Rentabilité des actifs | -39,90 % | — |
Retour sur capitaux | -43,18 % | — |
Flux de trésorerie
Variation nette en trésorerie
(USD) | mars 2024info | Variation Y/Y |
---|---|---|
Résultat net | -125,30 M | -357,42 % |
Trésorerie (opérations) | -92,38 M | -191,68 % |
Trésorerie (invest.) | -268,94 M | -645,70 % |
Trésorerie (financement) | 430,78 M | 82 741,73 % |
Variation nette en trésorerie | 69,49 M | 203,27 % |
Flux de trésorerie dispo. | -91,82 M | -262,49 % |
À propos
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Date de fondation
1 janv. 2004
Siège social
Site Web
Employés
525